(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/193578 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/00* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2025/019119

(22) International Filing Date:
10 March 2025 (10.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/563,793 11 March 2024 (11.03.2024) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors: **MARTINEZ RODRIGUEZ, Pablo**; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). **PARKES, Amanda**; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). **YU, Youfei**; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). **JIANG, Xun**; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US).

(74) Agent: **KISSLING, Heather, R.** et al.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: METHOD OF TREATING BRAIN METASTASES IN SUBJECTS WITH A DLL3-POSITIVE CANCER




FIG. 1

(57) Abstract: The disclosure provides a method of treating brain metastases in a human subject with a DLL3-positive cancer. The method comprises administering to the subject an anti-DLL3 agent comprising a first binding domain that binds to human DLL3 on the surface of a target cell and a second binding domain that binds to human CD3 on the surface of a T cell, wherein the anti-DLL3 agent is administered at a dose of from 3 mg to 200 mg once a week, once every two weeks, or once every three weeks.

WO 2025/193578 A1

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*